Finecure’s manufacturing scale is matched by the breadth of its therapeutic impact. The company formulates and manufactures Finished Dosage Forms (FDF) across 15+ therapeutic categories — capabilities proven daily through a domestic Branded Rx portfolio prescribed by over 40,000 healthcare practitioners.
Operating five specialised manufacturing blocks, Finecure delivers [capacity - use the company-profile figure] annually with consistent, zero-defect quality.
A 100% physically isolated beta-lactam block with independent HVAC, holding relative humidity below 20% — the condition moisture-sensitive Amoxicillin + Clavulanate requires for commercial-scale stability across tablets, dispersible tablets, and dry syrups. Why it matters: a de-risked, high-barrier supply line for one of the world’s most in-demand antibiotic combinations.
A separate, dedicated, PIC/S-approved cephalosporin injectable plant — segregated under GMP as cephalosporin manufacture legally requires, and independent of the Clavulanic block. Aseptic liquid and dry-powder vials for critical-care and institutional sterile supply. Why it matters: cephalosporins demand fully segregated manufacture; a dedicated, approved plant de-risks regulated-market sterile contracts.